These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24452809)

  • 1. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B.
    Diao L; Li S; Ludden T; Gobburu J; Nestorov I; Jiang H
    Clin Pharmacokinet; 2014 May; 53(5):467-77. PubMed ID: 24452809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
    Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
    Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
    Fischer K; Kulkarni R; Nolan B; Mahlangu J; Rangarajan S; Gambino G; Diao L; Ramirez-Santiago A; Pierce GF; Allen G
    Lancet Haematol; 2017 Feb; 4(2):e75-e82. PubMed ID: 28159192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
    Shapiro A; Chaudhury A; Wang M; Escobar M; Tsao E; Barnowski C; Feng J; Jain N; Quon DV
    Haemophilia; 2020 Nov; 26(6):975-983. PubMed ID: 33012060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eftrenonacog Alfa: A Review in Haemophilia B.
    Hoy SM
    Drugs; 2017 Jul; 77(11):1235-1246. PubMed ID: 28646426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.
    Shapiro AD; Ragni MV; Valentino LA; Key NS; Josephson NC; Powell JS; Cheng G; Thompson AR; Goyal J; Tubridy KL; Peters RT; Dumont JA; Euwart D; Li L; Hallén B; Gozzi P; Bitonti AJ; Jiang H; Luk A; Pierce GF
    Blood; 2012 Jan; 119(3):666-72. PubMed ID: 22110246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study.
    Pasi KJ; Fischer K; Ragni M; Kulkarni R; Ozelo MC; Mahlangu J; Shapiro A; P'Ng S; Chambost H; Nolan B; Bennett C; Matsushita T; Winding B; Fruebis J; Yuan H; Rudin D; Oldenburg J
    Haemophilia; 2020 Nov; 26(6):e262-e271. PubMed ID: 32497409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.
    Pasi KJ; Fischer K; Ragni M; Nolan B; Perry DJ; Kulkarni R; Ozelo M; Mahlangu J; Shapiro AD; Baker RI; Bennett CM; Barnes C; Oldenburg J; Matsushita T; Yuan H; Ramirez-Santiago A; Pierce GF; Allen G; Mei B
    Thromb Haemost; 2017 Feb; 117(3):508-518. PubMed ID: 28004057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.
    Powell J; Shapiro A; Ragni M; Negrier C; Windyga J; Ozelo M; Pasi J; Baker R; Potts J; Li S; Mei B; Pierce GF; Robinson B
    Br J Haematol; 2015 Jan; 168(1):113-23. PubMed ID: 25209873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the toxicology, pharmacokinetics, and local tolerance of recombinant factor IX Fc fusion protein in animals.
    Dumont JA; Loveday KS; Light DR; Pierce GF; Jiang H
    Thromb Res; 2015 Aug; 136(2):371-8. PubMed ID: 25840744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged activity of factor IX as a monomeric Fc fusion protein.
    Peters RT; Low SC; Kamphaus GD; Dumont JA; Amari JV; Lu Q; Zarbis-Papastoitsis G; Reidy TJ; Merricks EP; Nichols TC; Bitonti AJ
    Blood; 2010 Mar; 115(10):2057-64. PubMed ID: 20056791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.
    Sommer JM; Buyue Y; Bardan S; Peters RT; Jiang H; Kamphaus GD; Gray E; Pierce GF
    Thromb Haemost; 2014 Nov; 112(5):932-40. PubMed ID: 25144892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
    Sommer JM; Sadeghi-Khomami A; Barnowski C; Wikén M; Willemze AJ
    Int J Lab Hematol; 2020 Jun; 42(3):350-358. PubMed ID: 32202380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.
    Preijers T; van Spengler MWF; Meijer K; Fijnvandraat K; Fischer K; Leebeek FWG; Cnossen MH; Mathôt RAA
    Eur J Clin Pharmacol; 2022 Feb; 78(2):237-249. PubMed ID: 34651201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B.
    Suzuki A; Tomono Y; Korth-Bradley JM
    Haemophilia; 2016 Sep; 22(5):e359-66. PubMed ID: 27353956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
    Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
    J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort.
    O'Donovan M; Bergin C; Quinn E; Singleton E; Roche S; Benson J; Bird R; Byrne M; Duggan C; Gilmore R; Ryan K; O'Donnell JS; O'Connell NM
    Haemophilia; 2021 Jul; 27(4):618-625. PubMed ID: 33939224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.